Institutional Fund
Gilead Sciences, Inc.
Foster City, CACIK 8820955 filings on record
Portfolio Value
$2.12B
Q1 2026
Holdings
6
Reported positions
New Buys
0
Opened this quarter
QoQ Change
+9.4%
from $1.94B
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Arcellx Inc36.4%
- Arcus Biosciences Inc32.1%
- Galapagos NV23.7%
- Assembly Biosciences Inc5.9%
- Kyverna Therapeutics Inc1.7%
- Xilio Therapeutics Inc0.3%
Portfolio Holdings
6 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Arcellx Inc | 6.72M | $771.68M | 36.4% | 0 | Held |
| 2 | Arcus Biosciences Inc | 31.42M | $678.77M | 32.1% | 0 | Held |
| 3 | Galapagos NV | 16.71M | $501.22M | 23.7% | 0 | Held |
| 4 | Assembly Biosciences Inc | 4.51M | $125.02M | 5.9% | 0 | Held |
| 5 | Kyverna Therapeutics Inc | 4.13M | $35.61M | 1.7% | 0 | Held |
| 6 | Xilio Therapeutics Inc | 650.4K | $5.47M | 0.3% | −8.46M | Reduced |